CGP 20376

CAS No. 81059-04-3

CGP 20376( —— )

Catalog No. M34544 CAS No. 81059-04-3

CGP 20376 is a benzothiazole compound, an anthelmintic, with dual dose-dependent modulation of in vitro effects on the respiratory burst of eosinophils and antifibrillatory properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 698 In Stock
10MG 938 In Stock
25MG 1454 In Stock
50MG 1841 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CGP 20376
  • Note
    Research use only, not for human use.
  • Brief Description
    CGP 20376 is a benzothiazole compound, an anthelmintic, with dual dose-dependent modulation of in vitro effects on the respiratory burst of eosinophils and antifibrillatory properties.
  • Description
    CGP 20376 is a benzothiazole compound, an anthelmintic, with dual dose-dependent modulation of in vitro effects on the respiratory burst of eosinophils and antifibrillatory properties.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    81059-04-3
  • Formula Weight
    384.54
  • Molecular Formula
    C16H20N2O3S3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C(SCCC(O)=O)=S)C=1C=C2C(=CC1OC)N=C(C(C)(C)C)S2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Moth Cytochrome C (M...

    Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes.This peptide is derived from the carboxyl terminus of moth cytochrome c. Thymic positive and negative selections govern the development of a self-MHC-reactive, yet self-tolerant, T cell repertoire.

  • Clivatuzumab

    Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.

  • Bretylium tosylate

    Bretylium tosylate is an inhibitor of the presynaptic release of vasoconstrictor neurotransmitters a available antiarrhythmic drug for ventricular arrhythmias.